The Evolving Brain Cancer Landscape
Brain and CNS cancers remain disproportionately lethal, ranking 12th in mortality despite being only 19th in prevalence. With cases and deaths projected to rise sharply by 2045, there is an urgent need for more effective therapeutic strategies.
With exclusive data from Beacon, this report contains insights into:
- Biomarkers: EGFR & HER2 are the most studied biomarkers, with trials mainly in phase 1 & 2
- Therapeutics: Small molecules lead late-stage development, due to blood-brain-barrier penetration
- Targets: B7-H3 & EGFRviii are key targets driving innovative drug development
- First Time Approvals: Six new therapies, including vorasidenib and tovorafenib, gained approval since 2021
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
